VETOQUINOL
Vetoquinol (Paris: VETO) is delighted to announce that Felpreva® is now available for veterinarians to prescribe in five European markets including France, Germany, United Kingdom, Austria and Italy.
Felpreva® is an innovation in companion animal parasitology. It is the first three-monthly spot-on parasiticide for cats that covers tapeworms in addition to other endoparasites (lungworms, roundworms and hookworm) and ectoparasites (fleas, ticks and mites) in a single dose. It is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections.1
Felpreva® ’s broad-spectrum active ingredients cover:
Endoparasites:
- Gastrointestinal roundworms: infection with Toxocara cati
, Toxascaris leonina
and Ancylostoma tubaeforme
- Lungworms: infection with Aelurostrongylus abstrusus
and Troglostrongylus brevior
- Tapeworms: infection with Dipylidium caninum
and Taenia taeniaeformis
Ectoparasites:
- Flea (Ctenocephalides felis
), tick (Ixodes ricinus, Ixodes holocyclus
) and mite (Otodectes cynotis
) infestations, as well as mild to moderate cases of notoedric mange (caused by Notoedres cati
). It can also form part of a treatment strategy for flea allergic dermatitis (FAD).
Matthieu Frechin, Vetoquinol CEO, commented: “The launch of Felpreva® is a truly proud moment for Vetoquinol, demonstrating our expertise, passion, and commitment to innovation in this essential category of veterinary medicine. As a product that has been designed specifically for cats with the needs of veterinarians and cat owners in mind, we look forward to Felpreva® realising its potential in helping safeguard the health of cats around the world.”
A recent survey revealed that 44% of cat owners said that giving parasite protection to their cat was a negative experience.2 Therefore reducing the frequency of treatments, thanks to Felpreva® , will also reduce stressful interactions between cats and their owners, and will result in a more positive experience for all, with the ultimate goal to increase compliance and thus improve parasite protection for cats.
Juliana Carrer, International Range Manager at Vetoquinol, and a qualified veterinarian, highlights the importance of simplicity for both veterinarians and cat owners. She said: “The need for a straightforward, cat-friendly endectocide solution like Felpreva® has never been more critical. Time-poor vets are faced with increasing numbers of feline patients, whilst owners continue to struggle with the stress of treating their cats. We are so pleased that Felpreva® is now here to ease veterinarians’ decision-making, encourage owner compliance, and improve health outcomes for cats.”
For more information on Felpreva® please contact your local Vetoquinol representative.
ENDS
ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,540 people as of September 30th, 2021.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.
For further information, go to: www.vetoquinol.com
1
European Commission Union Register of Veterinary Medicinal Products – Felpreva. 2021. Available from: https://ec.europa.eu/health/documents/community-register/html/v277.htm
[Accessed 16 November 2021].
2
Vetoquinol market research [data on file].
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005607/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press release
Deseyne® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia Correction The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifoc
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press release
Five-year contract to drive innovation in stimulation, intervention, digital and frac automationAgreement underscores gas as a pivotal fuel for global energy demand and a bridge to lower-carbon systems Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconve
Tabelog, Japan's Largest (*1)Restaurant Search and Reservation Service,Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press release
Experience Japan's Authentic Culinary Scene in Your Language — From Search to Reservation, All on Your SmartphoneRanked No. 1 in Downloads Among "Japanese Gourmet Search Apps" Chosen by International Travelers (*2) Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photo
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
I-care Becomes a Unicorn23.12.2025 10:45:00 CET | Press release
The Belgian company has surpassed the billion-euro valuation mark following a €20 million fundraising and refinancing round. I-care announces the completion of a €20 million fundraising and refinancing operation, carried out as a round reserved for existing shareholders and employees. Based on this operation, the group's valuation reaches €1 billion, making I-care a unicorn. "Becoming a unicorn is a symbolic milestone. To achieve this, we chose to invest before reaping the rewards: we bet on AI when few believed in it, we prioritized R&D, and we built our own production unit. These choices were sometimes difficult, but they were essential to staying ahead of the game. Today, our results confirm that this strategy was the right one," explains Fabrice Brion, CEO of I-care. This fundraising round is the first step in a three-phase development plan. Following the “Eau Rouge” operation in 2022, which enabled I-care to become the world leader in predictive maintenance, the company has now se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom